CompletedNot Applicable

Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy

Pakistan120 participantsStarted 2022-09-01

Plain-language summary

Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation. The study aims to compare ultra-widefield fluorescein angiography-based targeted retinal photocoagulation and panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * proliferative diabetic retinopathy (PDR) with neovascularization on the disc or elsewhere in the retina Exclusion Criteria: * Participants with a history of previous history of: * retinal photocoagulation * vitreoretinal surgery * tractional retinal detachment * epiretinal membrane * vitreomacular traction * glaucoma * uveitis * media opacities like cataract, corneal opacity, vitreous hemorrhage * anti-VEGF injections in last 3 months

What they're measuring

BCVA

Timeframe: 2 months

CMT

Timeframe: 2 months

VFI

Timeframe: 2 months

Trial details

NCT IDNCT06653361

SponsorHayatabad Medical Complex

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-02-28

View on ClinicalTrials.gov More Proliferative Diabetic Retinopathy - High Risk trials